Combination therapy targeting toll like receptors 7, 8 and 9 eliminates large established tumors

BACKGROUND: The TLR7/8 agonist 3M-052 and the TLR9 agonist CpG ODN both trigger innate immune responses that support the induction of tumor-specific immunity. Previous studies showed that these agonists used individually could improve the survival of mice challenged with small tumors but were of lim...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhao, By Gan, Vasilakos, John P, Tross, Debra, Smirnov, Dmitri, Klinman, Dennis M
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2014
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4075973/
https://www.ncbi.nlm.nih.gov/pubmed/24982761
http://dx.doi.org/10.1186/2051-1426-2-12

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4075973/
https://www.ncbi.nlm.nih.gov/pubmed/24982761
http://dx.doi.org/10.1186/2051-1426-2-12

Ejemplares similares